Quarterly report [Sections 13 or 15(d)]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Segment Expenses (Details)

v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Total Research and development expense $ 3,492 $ 2,428
Total General and administrative expense 2,012 2,356
Total operating expenses 5,504 4,784
Reportable Segment    
Segment Reporting Information [Line Items]    
Employee expenses 3,039 2,559
Consulting and professional fees 415 649
Clinical study expenses 5 241
Product development 709 195
Other 304 281
Total Research and development expense 1,433 1,366
General and administrative expenses 735 774
Commercialization readiness expenses 297 85
Total General and administrative expense 1,032 859
Total operating expenses $ 5,504 $ 4,784